DNA topoisomerase I and II in cancer chemotherapy: update and perspectives

Cancer Chemotherapy and Pharmacology

Volumn 32, Issue 2, 1993, Pages 103-108

  Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10,11 METHYLENEDIOXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; AMSACRINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; IDARUBICIN; TOPOTECAN; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; BINDING SITES; CAMPTOTHECIN; CELL DIFFERENTIATION; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG DESIGN; DRUG RESISTANCE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN; NEOPLASMS;

EID: 0027276902     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00685611     Document Type: Review

References (99)

1. Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death
2. In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction
3. Cell death induced by topoisomerase inhibitors: role of calcium in mammalian cells
4. Differential induction of secondary fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression
5. Transcription-dependent DNA supercoiling in yeast DNA topoisomerase mutants
6. Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA [published erratum appears in Nature 326(6115): 812]
7. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide
8. Association of crossover points with topoisomerase I cleavage sites: a model for nonhomologous recombination
9. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin
10. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA affinity and cytotoxicity
11. Mechanistic aspects of type-I topoisomerases
12. Effect of 4-beta-arylamino derivatives of 4′- O-demethylepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants
13. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells
14. Abrogation of etoposide-mediated cytotoxicity by cycloheximide
15. Characterization and immunological identification of cDNA clones encoding two human topoisomerase II isoenzymes
16. Transformed mammalian cells are deficient in kinase-mediated control of progression through the G1 phase of the cell cycle
17. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment
18. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons
19. DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication
20. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme
21. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
22. DNA topoisomerase from rat liver: physiological variations
23. Topoisomerase II is a structural component of mitotic chromosome scaffolds
24. Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome
25. Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative
26. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage
27. Role of DNA topoisomerase I in the transcription of supercoiled rDNA gene
28. Cohabitation of scaffold binding regions with upstream/enhancer elements of three developmentally regulated genes of D. melanogaster
29. Supercoiling of intracellular DNA can occur in eukaryotic cells
30. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts
31. Purification and characterization of a type II DNA topoisomerase from bovine calf thymus
32. Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle
33. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II
34. DNA topoisomerase II is required at the time of mitosis in yeast
35. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells
36. Mode of action of the new quinolones: new data
37. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
38. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells
39. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs
40. Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
41. Purification and properties of type II DNA topoisomerase from embryos of Drosophila melanogaster
42. Mutational alterations of the breakage/resealing subunits of bacteriophage T4 DNA topoisomerase confers resistance to antitumor agent m-AMSA
43. Induction of topoisomerase II gene expression in human lymphocytes upon phytohemagglutinin stimulation
44. Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin
45. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity
46. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin
47. DNA sequence at sites of topoisomerase I cleavage induced by camptothecin in SV40 DNA
48. SK&F 10864, a water-soluble analog of camptothecin with broad-spectrum activity in preclinical tumor models
49. Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q 12–13.2
50. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse
51. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note
52. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity
53. Function of DNA topoisomerases as replication swivels in Saccharomyces cerevisiae
54. Characterization of a camptothecin-resistant human DNA topoisomerase I
55. DNA topoisomerases as potential targets of antiviral action
56. Antitumor activity of 7-ethyl-10-[1-piperidino)-l-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors
57. DNA topoisomerase poisons as antitumor drugs
58. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship
59. A homogeneous type II DNA topoisomerase from HeLa a cell nuclei
60. Isolation of intercator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II
61. Phase 1 clinical trial of weekly and daily treatment with camptothecin (NSC-100800): correlation with preclinical studies
62. Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA
63. Single-strand DNA cleavages by eukaryotic topoisomerase II
64. Disassembly of the nucleus in the mitotic extracts: membrane vesiculization, lamin disassembly, and chromosome condensation are independent processes
65. 10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells
66. DNA topoisomerase II from Drosophila melanogaster. Relaxation of supercoiled DNA
67. Topoisomerase II inhibition by antitumor intercalators and demethylepipodophyllotoxins
68. Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells
69. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors
70. Role of DNA intercalation in the inhibition of purified mouse leukemia (L1210) DNA topoisomerase II by 9-aminoacridines
71. Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (CD3F) and resistant (DC3F/9-OHE) Chinese hamster cells
72. Distribution of topoisomerase II cleavage sites in SV40 DNA and the effects of drugs
73. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine and teniposide
74. Structure activity relationship of topoisomerase I inhibition by camptothecin derivatives: evidence for the existence of a ternary complex
75. The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I
76. Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerase I inhibitor
77. Stimulation of the topoisomerase II induced cleavage sites in the c-myc protooncogene by antitumor drugs is associated with gene expression
78. The topoisomerase II inhibitor VM-26 induces marked changes in histone H1 kinase activity, histones H1 and H3 phosphorylation, and chromosome condensation in G2 phase and mitotic BHK cells
79. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA
80. E-ring desoxy analogues of etoposide
81. Inhibition of protein synthesis reduces the cytotoxicity of 4′-(9-acridinylamino)methane-sulfon- m-anisidide without affecting DNA breakage and DNA topoisomerase II in a murine mastocytoma cell line
82. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients
83. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action
84. Structure-activity relations, cytotoxicity and topoisomerase II dependent DNA cleavage induced by pendulum ring analogues of etoposide
85. Acidic phospholipids directly inhibit DNA binding of mammalian DNA topoisomerase I
86. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II
87. Antitumor agents: 78. Inhibition of human DNA topoisomerase II by podophyllotoxin and alpha-peltatin analogues
88. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22
89. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe
90. A new look at older drugs in cancer treatment: natural products
91. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
92. Topoisomerase I-mediated integration of hepadnavirus DNA in vitro
93. DNA topoisomerases
94. Recent studies of DNA topoisomerases
95. DNA topoisomerases: why so many?
96. Teniposide, a topoisomerase II inhibitor, prevents chromosome condensation and separation but not decondensation in fertilized surf clam (Spisula solidissima) oocytes
97. Transcription generates positively and negatively supercoiled domains in the template
98. Characterization of the 3′ region of the human DNA topoisomerase I gene
99. Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities towards monocytoid differentiation